14 Results for "

demyelinating disease

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "demyelinating disease" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-108831A
CAS No.: 189261-10-7
Purity:  98.72%
Synonyms: AN100226; BG00002
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-108831
CAS No.: 189261-10-7
Purity:  99.10%
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P5982
PTPσ Inhibitor, ISP is a PTPσ intracellular wedge domain mimetic peptide containing a TAT cell-penetrating domain, which acts as a PTPσ inhibitor. PTPσ Inhibitor, ISP binds to and inhibits PTPσ, thereby relieving CSPG-mediated axonal growth inhibition. PTPσ Inhibitor, ISP enhances CSPG degradation by promoting the secretion of Cathepsin B or MMP-2, and promotes DRG axonal growth, OPC migration and remyelination. PTPσ Inhibitor, ISP promotes nerve regeneration and improves sensory, motor and urinary functions in animal models of spinal cord injury, dorsal root injury and multiple sclerosis. PTPσ Inhibitor, ISP also increases the phosphorylation of ERK and AKT in colorectal cancer cells. PTPσ Inhibitor, ISP can be used in studies related to PTPσ/CSPG signaling, nerve regeneration, demyelinating diseases and RAS/ERK signaling .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10441A
Target:  

Peptides

Research Areas:  

Inflammation/Immunology

S-palm P0(180–199) (TFA) is a peptide that enhances MHC II-restricted responses. S-palm P0(180–199) (TFA) can be used to establish models of chronic inflammatory demyelinating polyneuropathy (CIDP) and chronic experimental autoimmune neuritis (c-EAN). S-palm P0(180–199) (TFA) is used for studying autoimmune-mediated neuroinflammatory diseases .
loading...
    loading...
Cat. No.: HY-P990091
CAS No.: 2756228-76-7
Synonyms: SAR 445088
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-125222
CAS No.: 2247733-08-8
Purity:  98.02%
Target:  

Dynamin

Research Areas:  

Others

Drp1-IN-1 is a dynamin-1-like protein (Drp1) inhibitor with an IC50 of 0.91 μM. Drp1 mediates the fission of the outer mitochondrial membrane. Drp1-IN-1 can be used to study diseases associated with mitochondrial dysfunction .
loading...
    loading...
Cat. No.: HY-P2459
CAS No.: 163158-19-8
Target:  

Peptides

Research Areas:  

Inflammation/Immunology

MOG (35-55), human is a synthetic encephalitogenic peptide fragment (residues 35-55) of human myelin oligodendrocyte glycoprotein, and also serves as a myelin oligodendrocyte glycoprotein peptide epitope. MOG (35-55), human induces mild central nervous system inflammation in mice, but does not trigger demyelinating lesions, only causing mild clinical neurological symptoms. MOG (35-55) induces experimental autoimmune encephalomyelitis mouse models that recapitulate the features of optic neuritis, multiple sclerosis, myelin oligodendrocyte glycoprotein antibody-associated diseases, and neuromyelitis optica spectrum disorders .
loading...
    loading...
Cat. No.: HY-170035
CAS No.: 95119-86-1
Synonyms: C18 Glucosyl(β) ceramide (d18:1/18:0); D-glucosyl-β-1,1' N-stearoyl-D-erythro-sphingosine
Target:  

Fungal Wnt β-catenin

Research Areas:  

Infection Neurological Disease Cancer

GlcCer (d18:1/18:0) (C18 Glucosyl(β) ceramide (d18:1/18:0)) is a glycosphingolipids that activates the Wnt/β-catenin pathway by targeting LRP6. GlcCer (d18:1/18:0) drives EMT, migration, invasion and GBA1-mediated liver cancer metastasis. GlcCer (d18:1/18:0) accumulates to impair lysosomal function and induce toxic α-synuclein aggregation. GlcCer (d18:1/18:0) supports growth, sporulation, germination and virulence in Penicillium digitatum. GlcCer (d18:1/18:0) is reduced in demyelinated mouse corpus callosum. GlcCer (d18:1/18:0) can be used for the research of liver cancer, synucleinopathies, fungal, Parkinson’s disease and Gaucher disease .
loading...
    loading...
Cat. No.: HY-160207
CAS No.: 2156649-32-8
Synonyms: MA-JD21; ABX-002
Elunetirom (MA-JD21) is an orally active, blood-brain barrier-permeable prodrug of LL-340001. Elunetirom employs fatty acid amide hydrolase (FAAH)-dependent prodrug technology to enhance the brain delivery of LL-340001, a potent thyroid hormone receptor agonist with 15-fold higher selectivity for TRβ over TRα. Elunetirom induces T3-regulated gene expression, including that of ABCD2. Elunetirom drives neuroplasticity and bioenergetic changes, and induces neurogenesis, neuritogenesis, and synaptogenesis. Elunetirom is applicable to research related to major depressive disorder and X-linked adrenoleukodystrophy .
loading...
    loading...
Cat. No.: HY-107901
CAS No.: 1902161-12-9
Target:  

PPAR

Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
loading...
    loading...
Cat. No.: HY-125313
CAS No.: 139896-80-3
PSB-1737 is a human-selective GPR17 agonist with an EC50 for human GPR17 of 270 nM, and its activity on murine GPR17 is relatively weak (EC50 > 10 μM). PSB-1737 shows no significant inhibition at the glycine binding site of NMDA receptors, and has no significant agonistic or antagonistic activity on P2Y receptor subtypes. PSB-1737 can be used in demyelinating diseases (such as multiple sclerosis) or inflammatory-related anemia .
loading...
    loading...
Cat. No.: HY-115777
CAS No.: 1675206-11-7
Target:  

ROR

Research Areas:  

Neurological Disease

ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.
loading...
    loading...
Cat. No.: HY-176784
CAS No.: 163913-87-9
Target:  

Others

Human MOG-specifying DNA is located at chromosome 6 within the human leukocyte antigen (HLA) gene locus. Human MOG-specifying DNA is exclusively expressed in the central nervous system (CNS) on the surface of myelin sheaths and oligodendrocytes (ODCs) processes, with unique methylation patterns in ODCs. Human MOG-specifying DNA can be used for inflammatory demyelinating diseases such as multiple sclerosis (MS) research .
loading...
    loading...
Cat. No.: HY-179606
CAS No.: 2877694-62-5
RWT9996 is a GPR17 antagonist. RWT9996 inhibits GPR17-mediated signal transduction processes, including G protein activation and β-arrestin-2 recruitment. RWT9996 inhibits MDL-29951 (HY-16312)-mediated phosphorylation of ERK1/2, phosphorylation of CREB, and accumulation of inositol phosphate (IP1) in oligodendrocyte precursor cells in vitro. RWT9996 can be used in studies related to demyelinating diseases .
loading...
    loading...
  • 1